Alla Samoylova, Head, Federal Service for Surveillance in Healthcare (Roszdravnadzor)
The recent years’ experience has shown economic feasibility of centralized supply of medicinal products. Performance-based agreements for new medicines and various innovative procurement arrangements have been applied in all countries with developed health systems since the early 2000s. But, despite the obvious advantages and a number of pilot projects implemented, these new models are not approved at the federal level due to disagreements.
Issues for discussion: • What are the positive aspects of centralized procurement, what risks are important to foresee when expanding centralized procurement practices? • Why do European countries unite for joint procurement of medicinal products? • What needs to be done to benefit from new procurement arrangements?